Sorafenib and sunitinib: A dermatologist's perspective.

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Sorafenib and sunitinib are targeted therapies inhibiting tumor angiogenesis.
• These drugs are used in treating renal cell carcinoma and hepatocellular carcinoma.
• Cutaneous toxicities are common and can significantly impact treatment adherence.

Purpose of the Study:

• To review the pathophysiology of drug-induced cutaneous toxicities.
• To detail the adverse cutaneous effects and their grading.
• To discuss management strategies for hand-foot skin reactions.

Main Methods:

• Literature review of studies on sorafenib and sunitinib.
• Analysis of pathophysiology and clinical presentation of skin toxicities.
• Evaluation of risk factors and genetic influences.
• Review of management and prevention strategies.

Main Results:

• Cutaneous toxicities, including hand-foot skin reaction, are frequent side effects.
• Severity can necessitate dose modification or treatment interruption.
• Risk factors and genetic polymorphisms may influence toxicity development.
• Early recognition and management are crucial.

Conclusions:

• Understanding the mechanisms of cutaneous toxicity is key.
• Effective management strategies can improve patient outcomes and treatment continuity.
• Further research into predictive factors and targeted interventions is warranted.